Characteristics of antibiotics market
1. Most big pharma companies are active in the market and there is no single market-leading drug or class. Instead, a number of blockbusters from different classes and for different indications are dominating the scene.
- total sales : $25.5 billion (7 major markets in 2005), CAGR : 5.1% (2001~2005)
2. The antibiotics market is highly genericized but branded products still account for the main part of sales.
- branded products : 73% total sales achieved with as little as 19% of total prescription volume (US in 2005)
3. Although the community market is still dominant, the hospital market is gaining importance.
- the hospital market has been gaining sales market share with a CAGR of 8.8% (2001~2005)
MRSA drugs are a main source of overall antibacterial market growth
Growth drivers : increasing incidence, emerging resistances, high drug prices
Expected CAGR 2005-2015 : 14.8%
1. Oral MRSA drugs: With MRSA incidence rising in the community, oral drugs have a large commercial potential.
2. Gram-negative resistance: Carbapenems and tigecycline are the only available treatment options for severe gram-negative infections. Upon emergence of resistances, novel drugs are a crucial need.
3. Compounds outside previous drug classes: Most compounds currently in development are derivatives of existing drugs with low potential to overcome resistances in the mid- to long term.